6GJ Stock Overview
An ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Glaukos Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$132.00 |
| 52 Week High | US$140.00 |
| 52 Week Low | US$53.50 |
| Beta | 1.03 |
| 11 Month Change | 9.09% |
| 3 Month Change | 13.79% |
| 1 Year Change | 131.58% |
| 33 Year Change | 206.98% |
| 5 Year Change | 129.57% |
| Change since IPO | 432.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6GJ | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -5.7% | -2.5% | -1.3% |
| 1Y | 131.6% | -8.4% | 7.4% |
Return vs Industry: 6GJ exceeded the German Medical Equipment industry which returned -7.1% over the past year.
Return vs Market: 6GJ exceeded the German Market which returned 7.1% over the past year.
Price Volatility
| 6GJ volatility | |
|---|---|
| 6GJ Average Weekly Movement | 6.3% |
| Medical Equipment Industry Average Movement | 5.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6GJ has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 6GJ's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 907 | Tom Burns | www.glaukos.com |
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company’s product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Glaukos Corporation Fundamentals Summary
| 6GJ fundamental statistics | |
|---|---|
| Market cap | €7.44b |
| Earnings (TTM) | -€142.69m |
| Revenue (TTM) | €343.77m |
21.5x
P/S Ratio-51.9x
P/E RatioIs 6GJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6GJ income statement (TTM) | |
|---|---|
| Revenue | US$360.35m |
| Cost of Revenue | US$84.28m |
| Gross Profit | US$276.06m |
| Other Expenses | US$425.64m |
| Earnings | -US$149.57m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.71 |
| Gross Margin | 76.61% |
| Net Profit Margin | -41.51% |
| Debt/Equity Ratio | 8.5% |
How did 6GJ perform over the long term?
See historical performance and comparison